-
[2021 ASCO-GU] Multi-swords and Combinations | Combination Therapy: A powerful tool for the treatment of prostate cancer?
Time of Update: 2021-03-22
*Only for medical professionals to read for reference. From February 11 to 13, 2021, the American Society of Clinical Oncology Symposium on Urogenital Cancer (ASCO-GU 2021) was successfully held on
-
"Bladder" no longer ASCO-GU: immunotherapy strongly breaks through the difficulties of bladder cancer assistance, DFS will eventually double
Time of Update: 2021-03-22
"CheckMate-274 is the first and currently the only phase III clinical study that confirmed immunotherapy as an adjuvant treatment for myometrial invasive urothelial carcinoma, and achieved positive results in all random populations and those with PD-L1 expression ≥1%.
-
Quick five tests, easy to get the differential diagnosis of overactive bladder
Time of Update: 2021-03-22
In addition, according to the 2019 guidelines of the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), the symptoms of overactive bladder have four components: urgency, frequent urination, nocturia, and urgency.
According to the 2019 AUA/SUFU guidelines, urge incontinence, nocturia, and frequent urination are common symptoms of overactive bladder.
-
2021 ASCO-GU: Future | Advances in precision diagnosis and treatment of prostate cancer
Time of Update: 2021-03-22
At present, the use of next-generation sequencing (NGS) technology to detect circulating tumor cells (CTC) in the plasma of patients with metastatic castration-resistant prostate cancer (mCRPC) is an important non-invasive genetic testing method.
